What AGP does

AGP Limited (branded as AGP Pharma) is a Karachi-headquartered, publicly listed pharmaceutical manufacturer founded in 1989, operating two cGMP-compliant plants in the SITE industrial area of Karachi and producing tablets, capsules, syrups, suspensions, sachets, liquid parenteral and semi-solid preparations across more than 20 owned brands spanning Internal Medicine, Gynaecology, Pediatrics, Orthopedic, Cardiometabolic and Neuropsychiatry. Its portfolio includes legacy anchors such as Rigix (cetirizine), Ceclor (cefaclor), Keflex (cephalexin) and Nebcin (tobramycin), specialty brands including the Hertraz trastuzumab biosimilar, MyHep/MyHep All/MyDekla (Hepatitis C antivirals), TruGlif/TruGlif Met (SGLT2 inhibitors), the Gluconorm anti-diabetic family and Calfina analgesics, plus a differentiated proprietary Liposomal Iron Delivery Technology (Lipomax/Lipomax J). Quality and compliance are anchored by an independently implemented Quality Management System, IQ/OQ/PQ qualification of equipment, ISO 9001:2015 certification, and audits by multiple international customers.

AGP operates three distinct revenue streams. First, branded pharmaceutical sales distributed nationwide through a partnership with Muller & Phipps (M&P), the largest distribution house in Pakistan, and an internal field sales force conducting ethical promotion, medical seminars and ward presentations. Second, licensing and co-marketing royalties earned by manufacturing and marketing products from global pharmaceutical partners — Viatris, Vifor, OM Pharma, Dr. Kade, Besins Healthcare, AVVA Pharma, Osmopharm and SFI Health — for the Pakistan market. Third, direct export sales into Afghanistan, Sri Lanka, Kenya, Botswana and Cambodia, with publicly stated plans to enter Francophone Africa, Central America, Far East Asia and CIS regions. End-customer pricing is set per SKU at the pharmacy, institutional and export channel level and is not publicly disclosed.

AGP recently completed an Initial Public Offering on the Pakistan Stock Exchange (PSX) — described on its website as the 'Largest IPO in Pakistan's Pharmaceutical Industry' — via an Offer for Sale, with a gong-ringing ceremony held at PSX to mark the listing. The company supports its operations with standard digital systems (IQVIA Sales Analyzer, Softrack HR, LMS, Sunny Portal ennexOS, PSW and DRAP IE-system integrations), a 24-hour temperature-controlled warehouse, and ongoing cybersecurity awareness training; it does not disclose proprietary AI/ML capabilities. The firm employs 1,001–5,000 staff across manufacturing, marketing, distribution, R&D, quality, EHS and corporate affairs and is recognised in industry awards including SAFA Best Presented Annual Report (Silver 2024), BCSR Awards (1st in pharma 2023 and 2024), the 22nd Annual Environment Excellence Award 2025, the PESA Awards 2025 and the Top Exporter Award at the 6th PPMA Summit.

Name

AGP

Legal name

AGP Limited

Website

https://agp.com.pk

Company type

Public

Founded year

1989

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

AGP Limited is a Karachi-based, PSX-listed pharmaceutical manufacturer (founded 1989) that produces and markets 20+ branded drugs across six therapeutic categories via two cGMP plants, distributes through Muller & Phipps, in-licenses from global pharma partners, and exports to South Asia, East Africa, Southern Africa and Southeast Asia.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (424210), Drugs and Druggists' Sundries Merchant Wholesalers (42421), Pharmaceutical Preparation Manufacturing (325412)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Pharmaceutical Preparations (2834)

akta.pro primary industry

Specialty Pharmaceutical Distributors (HLAIAJAB)

akta.pro secondary industry

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

Keywords

• Pharmaceutical manufacturing
• Generic medicines
• Licensed drug production
• Oral solid dosage
• Biosimilar products

Headquarters

HQ city

Karachi

HQ country

Pakistan

HQ region

Asia

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Pharmaceutical Product Sales (Branded): Sales of more than 20 own brands across therapeutic categories (Internal Medicine, Gynaecology, Pediatrics, Orthopedic, Cardiometabolic, Neuropsychiatry) including flagship products Rigix, Ceclor, Keflex, Nebcin, PeriDots, and others; distribution via Muller & Phipps and through the company's own commercial operations.
2. Licensing & Co-Marketing Royalties: Revenue from manufacturing and marketing internationally-licensed products in Pakistan under arrangements with Viatris, Vifor, OM Pharma, Dr. Kade, Besins Healthcare, AVVA Pharma, Osmopharm, and SFI Health.
3. Export Sales: Direct sales of pharmaceutical products to international markets including Afghanistan, Sri Lanka, Kenya, Botswana, and Cambodia, with planned expansion into Francophone, Central America, Far East Asia and CIS regions.

Pricing tiers

Go-to-market motion4 records

Core offering

AGP manufactures and markets a portfolio of more than 20 branded pharmaceutical products across six therapeutic categories — Internal Medicine, Gynaecology, Pediatrics, Orthopedic, Cardiometabolic and Neuropsychiatry — in dosage forms including tablets, capsules, syrup, suspension, sachets, liquid parenteral and semi-solid preparations. Manufacturing is conducted at two cGMP-compliant plants in Karachi's SITE industrial area and combines in-house proprietary brands with products manufactured and marketed under licensing and co-marketing arrangements with global pharmaceutical companies. Distribution in Pakistan is executed through Muller & Phipps, complemented by an enterprise field-sales force targeting prescribers.

Product overview

AGP's product offering is a multi-brand pharmaceutical portfolio rather than a single unified product or platform-plus-modules architecture. The portfolio is organized across multiple therapeutic categories with both legacy and recently launched brands. Specifically named products in the available source material include Rigix (a legacy core brand that received refreshed packaging), PeriDots (promoted on the homepage as a current launch), Cinklare (launched in April 2018), and Neogene Vial containing Ceftriaxone. The portfolio also includes numerous additional branded SKUs across therapeutic categories that are referenced collectively rather than individually in the source. Beyond proprietary brands, AGP operates in-licensed and co-marketed products from global partners (Viatris, Vifor, OM Pharma, Dr. Kade, Besins Healthcare, AVVA Pharma, Osmopharm, SFI Health), and distributes through the Muller & Phipps (M&P) distribution channel. The detailed composition of the broader portfolio beyond the four named products above is not enumerated in the available source data.

Differentiator

Problem solved

Functional benefit

Brands

• Rigix: Antihistamine brand (cetirizine) marketed in tablet, oral solution, drops and eye drop formulations.
• Ceclor
• Keflex
• Nebcin
• Hertraz
• PeriDots
• MyHep / MyHep All / MyDekla
• TruGlif / TruGlif Met
• Gluconorm / Gluconormet / Glyzia / Glyziamet / Poze / Poze G / Pozemet
• Calfina / Calfina CR / Calfina Plus / Calfina INJ

Products and services

• Rigix AGP's antihistamine brand (cetirizine) marketed in tablet, oral solution, drops and eye drop formulations for allergy treatment.
• Ceclor Second-generation cephalosporin antibiotic (cefaclor) marketed as capsules, MR tablets, oral suspension and drops.
• Keflex First-generation cephalosporin antibiotic (cephalexin) marketed as capsules, oral suspension and drops.
• Nebcin Aminoglycoside antibiotic (tobramycin) marketed under the Nebcin brand.
• Hertraz Trastuzumab biosimilar marketed under the Hertraz brand for HER2-positive breast and gastric cancer.
• PeriDots Peppermint and spearmint oil soft gelatin capsules marketed under the PeriDots brand for indigestion, acidity and heartburn.
• MyHep / MyHep All / MyDekla Hepatitis C antiviral portfolio comprising sofosbuvir (MyHep), sofosbuvir+velpatasvir (MyHep All) and daclatasvir (MyDekla).
• TruGlif / TruGlif Met SGLT2 inhibitor range based on empagliflozin (TruGlif) and empagliflozin+metformin (TruGlif Met) for type 2 diabetes.
• Gluconorm / Gluconormet / Glyzia / Glyziamet / Poze / Poze G / Pozemet Anti-diabetic portfolio spanning sulfonylureas, glitazones, DPP-4 inhibitors and combinations across the Gluconorm, Glyzia and Poze sub-ranges.
• Calfina / Calfina CR / Calfina Plus / Calfina INJ Analgesic range based on tramadol and paracetamol across the Calfina sub-brands (immediate-release, controlled-release, plus formulation and injectable).
• Lipomax / Lipomax J Iron supplement range built on AGP's proprietary liposomal delivery technology that microencapsulates iron pyrophosphate in a phospholipid membrane for improved gastrointestinal absorption and tolerability.
• Cinklare Pharmaceutical product launched by AGP in April 2018. The detailed therapeutic category, active ingredient and indication are not specified in the available source material.
• Neogene Vial (Ceftriaxone) Vial formulation of the injectable antibiotic ceftriaxone marketed under the Neogene brand. Specific strength and pack size are not stated in the available source material.

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Getz Pharma: Getz Pharma is the largest Pakistani pharmaceutical company by revenue and operates a directly comparable business model: branded generics manufacturing in Pakistan with a strong export focus, a multinational partnership pipeline, and a diversified therapeutic portfolio. It is AGP's closest direct domestic peer.
• The Searle Company Limited: Searle is a top-tier Pakistan-listed pharmaceutical manufacturer with a branded generics portfolio, in-licensed multinational products, and active export operations. Its therapeutic mix, manufacturing footprint in Karachi, and PSX listing make it one of AGP's most directly comparable domestic competitors.
• Hilton Pharma: Hilton Pharma is a Pakistan-based pharmaceutical manufacturer and marketer with a broad branded portfolio and multinational product licensing arrangements, operating in the same therapeutic categories and channels as AGP, including a focus on antibiotics, cardiology, and CNS.
• Ferozsons Laboratories Limited: Ferozsons is a PSX-listed Pakistani pharma manufacturer with branded generics, an in-licensing model (notably with Gilead for hepatitis C antivirals — directly comparable to AGP's MyHep franchise), and a manufacturing footprint, making it a direct peer in the same regulatory and competitive environment.
• Highnoon Laboratories Limited: Highnoon is a Pakistan-listed pharmaceutical company producing branded generics, with an in-licensing model and export operations. Its scale, therapeutic breadth, and PSX listing are directly comparable to AGP's positioning.
• Sami Pharmaceuticals (Pvt.) Limited: Sami Pharmaceuticals is a Pakistan-based manufacturer of branded generics with a focus on cardiovascular, anti-infective, and CNS therapies, plus an export business. Smaller than AGP but directly comparable in product mix and Pakistan-domestic market focus.
• Macter International Limited: Macter is a PSX-listed Pakistani pharmaceutical manufacturer producing branded generics for domestic and export markets, with a multinational partnership model. It competes with AGP in similar therapeutic categories and distribution channels.

Broad incumbents

• Abbott Laboratories Pakistan: Abbott Pakistan is the local subsidiary of a global pharmaceutical major and competes with AGP in the same branded generics and licensed-product categories in Pakistan. It is a broader incumbent with multinational balance-sheet and product support rather than a niche specialist.
• GlaxoSmithKline Pakistan Limited: GSK Pakistan is a PSX-listed subsidiary of a global pharma major and competes with AGP in antibiotics (Augmentin vs. AGP's Ceclor/Keflex), vaccines, and consumer health. Comparable as a broad incumbent rather than as a focused mid-cap generics player.

Emerging players

• Cipla Limited: Cipla is a major Indian generic manufacturer with strong presence across Africa, South Asia, and other emerging markets — directly relevant as a competitor in AGP's stated export markets (Kenya, Botswana, Sri Lanka, Cambodia). Comparable as a benchmark for export business model and pricing pressure rather than domestic Pakistani overlap.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/agp_limited
• YouTubeyoutube.com/channel/UC4Z1WQrhZXPW9ko7BCV-BlA
• Facebookfacebook.com/AGPPharmaceutical
• LinkedInlinkedin.com/company/agplimited
• Instagraminstagram.com/agplimited

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AGP